Evotec SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript
Evotec SE misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.03333.
Eaton Vance Ohio Municipal Income Trust (EVO)
Market is closed
News
- Displaying 5
Evotec SE (NASDAQ:EVO) Q3 2023 Earnings Call Transcript
Werner Lanthaler: Welcome to our -- good morning. Good afternoon. Welcome to our Q3 Call. Resilient into the Future of Biopharma R&D.
Does Evotec SE (EVO) Have Good Long-Term Growth Prospects?
Brown Capital Management, an investment management company, released its “The Brown Capital Management International Small Company Strategy” Q3 2022 investor letter.
10 Best Low Price Pharma Stocks To Buy Now
The global pharmaceuticals market was forecasted to grow from $1454.66 billion in 2021 to $1587.05 billion in 2022 at a compound annual growth rate (CAGR) of 9.1%.
5 Best Drug Stocks To Buy Now
Evotec SE (NYSE:EVO) is a German drug discovery, pharmaceutical, and biotechnology company that produces drug candidates for diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation...
Billionaire Hedge Funds
